Viberzi Lawsuit

Viberzi Overview

Patients without a gallbladder who took Viberzi and developed pancreatitis may be eligible to pursue a claim and seek financial compensation.

Viberzi is a medication used for patients with Irritable Bowel Syndrome with diarrhea (IBS-D), a condition which causes excessive gas, severe abdominal pains, and loose bowel movements. It was approved by the FDA in 2015. Lawsuits against the manufacturer of Viberzi were filed by patients and affected family members claiming the drug increases the risk of pancreatitis among users.

If you or a loved one was treated with Viberzi and suffered pancreatitis and other complications, contact Maxwell Law Group LLP today. We can answer your questions and review your case for free.

For help understanding your options if you’ve been injured by Viberzi, reach out to our firm or call (844) 525-7155.

What is Viberzi?

Viberzi (generic name: eluxadoline) is an oral medication prescribed for the treatment of Irritable Bowel Syndrome with diarrhea (IBS-D).

This condition causes excessive gas production, severe abdominal pain, and frequent loose bowels. Viberzi can lessen bowel movements and decrease abdominal pain.

FDA approved Viberzi in May 2015 for IBS-D treatment. Viberzi’s manufacturer is Allergan. Viberzi is expected to reach $365 million in sales by 2020.

Viberzi Quick Facts



Medication for Irritable Bowel Syndrome with diarrhea (IBS-D)



Pancreatitis in patients who had their gall bladder removed





How Does Viberzi Work?

Viberzi contains mixed opioid receptors: a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist. All of these reduce intestinal contractions and normalize the accelerated movement of the upper GI tract. The delta receptor antagonistic activity also minimizes the possible constipating effect that is usually caused by mu receptor agonists.

viberzi lawsuit overview

Risks and Warnings

In 2017, the FDA released a warning that Viberzi should not be used with patients who had their gallbladders removed. The FDA received reports of serious cases of pancreatitis from users of the drug who had previously had their gallbladders removed.

From May 2015 to February 2017, there were 120 reports of pancreatitis and death. Among the 68 patients who submitted their gallbladder status, 56 of them did not have a gallbladder. Roughly 48 of the cases developed soon after the first or second dose. Out of 120 cases, 76 patients were hospitalized, and 2 of them died. Both of the individuals who passed away had previously had their gallbladders removed, and both experienced severe abdominal pain and vomiting shortly after taking their first dose of Viberzi.

The time you have to pursue a claim is limited. Do not wait to reach out to our firm or call (844) 525-7155 to see if you have a case.

Injuries from Viberzi

In 2017, researchers from Fairleigh Dickinson University reviewed articles and clinical trials about eluxadoline (Viberzi). They gathered data from 45 Medline articles and 46 Pubmed articles using the search terms “eluxadoline”, “eluxadoline in IBS-D”, and “eluxadoline AND IBS-D”.

The researchers observed that eluxadoline causes Sphincter of Oddi spasms. Since this sphincter is the muscular valve that controls the flow of digestive juices, like bile and pancreatic enzymes, spasms tend to send back these juices to the pancreas. It was noted that patients without a gallbladder are especially at risk because the gallbladder stores excess bile. Pancreatitis was also the most reported severe adverse event of those taking Viberzi, with 0.2% of the cases occurring within the first 2 weeks of taking the drug.

Another study in 2016 looked into the safety of eluxadoline among IBS-D patients. Participants were observed in 3 groups, each spanning 12, 26, and 52 weeks. From a sample size of 2,776 patients, 10 experienced acute abdominal pain with elevated pancreatic enzyme levels. All of those who experienced the acute abdominal pain had previously had their gallbladder removed. The severe side effects occurred within the first week for 8 patients who were on higher doses of the drug, and all side effects disappeared when the users stopped taking Viberzi.

Viberzi Lawsuits

Patients and family members who have been affected by Viberzi are now filing lawsuits against its manufacturer, Allergan. The lawsuits claim that the company failed to warn the public about the serious side effects of the drug, specifically pancreatitis for those who have previously had their gallbladder removed.

The lawsuits allege that Allergan should have engaged in more exhaustive testing of Viberzi and identifying its risks before releasing it to the market. Unfortunately, Viberzi was prescribed to patients who had previously had their gallbladder removed for 2 years before the FDA warning was issued.

viberzi pancreatitis regulation timeline

How Maxwell Law Group Can Help

If you or your loved one had a gallbladder removed and suffered from pancreatitis after taking Viberzi, Maxwell Law Group can help get you the compensation you deserve. Call (844) 525-7155 or fill out the form below and we’ll investigate your case at no charge to you.

You Deserve to be Compensated

1 + 13 =

We're On Your Side

Our attorneys are always ready to speak with you about your personal situation. Every day we help people in situations similar to yours. Our team can guide you each step of the way and make sure you get the financial compensation you deserve.

While our physical offices are in Utah and Washington DC, we offer our services nationwide. We'd be honored to discuss your case with you free of charge.

Please note that the law limits the time you have to pursue a claim or file a lawsuit for an injury. If you think you have a case, don't wait to take action. Contact us today.

To speak with us directly, call (844) 525-7155. We want to hear about your situation and help you through this difficult time.

Maxwell Law Group LLP

Maxwell Law Group LLP
© 2021 All Rights Reserved

Washington DC Office

By appointment only
1101 Connecticut Avenue NW
Suite 450
Washington, D.C. 20036

Utah Office

520 N Marketplace Drive
Suite 200A
Centerville, UT 84014

ATTORNEY ADVERTISING. Nothing on this site should be taken as legal advice for any individual case or situation. This website is not intended to create, and receipt of viewing does not constitute, an attorney-client relationship. Sensitive information should not be submitted through this website as it may be considered confidential or privileged. References to prior results do not guarantee a similar outcome. The firm has attorneys licensed to practice law in Utah and Washington D.C., but the attorneys may also be admitted on an individual basis in additional state and federal courts across the United States. The location of the firm's offices are listed on this website. The firm associates with co-counsel law firms to jointly represent clients in some matters. Gregory Maxwell is the attorney responsible for the contents of this website.

Share via
Send this to a friend